Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry S Wolinsky

Showing results (81-90 of 139) with videos related to

Pageof 14
Sort By:
The Lancet. Neurology|September 7, 2014
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller, Jerry S Wolinsky, Ludwig Kappos, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2019
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MSEdward J Fox, Fred D Lublin, Jerry S Wolinsky, et al.
Brain : a Journal of Neurology|September 10, 2019
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosisColm Elliott, Shibeshih Belachew, Jerry S Wolinsky, et al.
The New England Journal of Medicine|May 11, 2019
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple SclerosisXavier Montalban, Douglas L Arnold, Martin S Weber, et al.
Multiple Sclerosis and Related Disorders|June 14, 2019
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study<sup>★★</sup>Aaron E Miller, Patrick Vermersch, Ludwig Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 14, 2019
Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale studyRefaat E Gabr, Ivan Coronado, Melvin Robinson, et al.
Journal of Neurology|March 2, 2019
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosisBenjamin Turner, Bruce A C Cree, Ludwig Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 23, 2012
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisAaron E Miller, Paul O'Connor, Jerry S Wolinsky, et al.
Multiple Sclerosis and Related Disorders|May 31, 2016
Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studiesMathias Mäurer, Giancarlo Comi, Mark S Freedman, et al.
JAMA Neurology|November 25, 2014
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for managementAnn M Arvin, Jerry S Wolinsky, Ludwig Kappos, et al.
Pageof 14

Showing results (81-90 of 139) with videos related to

Sort By:
Pageof 14
The Lancet. Neurology|September 7, 2014
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller, Jerry S Wolinsky, Ludwig Kappos, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2019
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MSEdward J Fox, Fred D Lublin, Jerry S Wolinsky, et al.
Brain : a Journal of Neurology|September 10, 2019
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosisColm Elliott, Shibeshih Belachew, Jerry S Wolinsky, et al.
The New England Journal of Medicine|May 11, 2019
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple SclerosisXavier Montalban, Douglas L Arnold, Martin S Weber, et al.
Multiple Sclerosis and Related Disorders|June 14, 2019
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study<sup>★★</sup>Aaron E Miller, Patrick Vermersch, Ludwig Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 14, 2019
Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale studyRefaat E Gabr, Ivan Coronado, Melvin Robinson, et al.
Journal of Neurology|March 2, 2019
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosisBenjamin Turner, Bruce A C Cree, Ludwig Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 23, 2012
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisAaron E Miller, Paul O'Connor, Jerry S Wolinsky, et al.
Multiple Sclerosis and Related Disorders|May 31, 2016
Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studiesMathias Mäurer, Giancarlo Comi, Mark S Freedman, et al.
JAMA Neurology|November 25, 2014
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for managementAnn M Arvin, Jerry S Wolinsky, Ludwig Kappos, et al.
Pageof 14